Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Invested Capital (2023 - 2025)

Monte Rosa Therapeutics' Invested Capital history spans 3 years, with the latest figure at $233.1 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 4.54% year-over-year to $233.1 million; the TTM value through Dec 2025 reached $233.1 million, up 4.54%, while the annual FY2025 figure was $233.1 million, 4.54% up from the prior year.
  • Invested Capital reached $233.1 million in Q4 2025 per GLUE's latest filing, down from $245.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $275.2 million in Q1 2025 to a low of $152.5 million in Q1 2024.
  • Average Invested Capital over 3 years is $220.7 million, with a median of $223.8 million recorded in 2024.
  • Peak YoY movement for Invested Capital: tumbled 37.42% in 2024, then soared 80.41% in 2025.
  • A 3-year view of Invested Capital shows it stood at $179.2 million in 2023, then increased by 24.37% to $222.9 million in 2024, then rose by 4.54% to $233.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Invested Capital are $233.1 million (Q4 2025), $245.8 million (Q3 2025), and $268.1 million (Q2 2025).